{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T01:36:41Z","timestamp":1766367401669,"version":"3.48.0"},"reference-count":30,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Thrombocytopenia induced by proton pump inhibitors (PPIs) is a relatively uncommon adverse effect of this widely prescribed class of drugs. The objective of this study is to investigate the clinical features of PPIs-induced thrombocytopenia based on published case reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched the PubMed, Web of Science, Scopus, China National Knowledge Infrastructure, Wanfang Data, and Chinese VIP databases from inception to August 2024 to identify reported cases of thrombocytopenia associated with PPIs use. Clinical data such as patient demographics, drug use information, adverse reactions, and outcomes were extracted and analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 16 publications describing 18 cases (12 males and 6 females) were included in this study, comprising a neonate and 17 adults with a median age of 62 years (range 23\u201398). The PPIs associated with thrombocytopenia included pantoprazole (11 cases), lansoprazole (4 cases), omeprazole (2 cases), and esomeprazole (1 case). The median time to symptoms onset was 3 days (range 2\u20137) after the initiation of PPI therapy. After discontinuation of PPIs and interventions such as platelet transfusion, 11 patients achieved recovery, and the remaining 7 patients experienced symptomatic improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Thrombocytopenia induced by PPIs appears to be a rare adverse event. Clinicians should enhance their awareness when evaluating potential cases of thrombocytopenia. Once PPIs are suspected, immediate discontinuation of the drugs and initiation of appropriate treatments are recommended.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/med-2025-1297","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:47:31Z","timestamp":1761767251000},"source":"Crossref","is-referenced-by-count":0,"title":["Proton pump inhibitors-induced thrombocytopenia: A systematic literature analysis of case reports"],"prefix":"10.1515","volume":"20","author":[{"given":"Xiaofei","family":"Yue","sequence":"first","affiliation":[{"name":"Rehabilitation Pharmacy Center, Beijing Rehabilitation Hospital, Capital Medical University , Beijing , 100144 , PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjiao","family":"Tian","sequence":"additional","affiliation":[{"name":"Rehabilitation Pharmacy Center, Beijing Rehabilitation Hospital, Capital Medical University , Beijing , 100144 , PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"2025122201304625408_j_med-2025-1297_ref_001","doi-asserted-by":"crossref","unstructured":"Maideen NMP. Adverse effects associated with long-term use of proton pump inhibitors. Chonnam Med J. 2023;59(2):115\u201327.","DOI":"10.4068\/cmj.2023.59.2.115"},{"key":"2025122201304625408_j_med-2025-1297_ref_002","doi-asserted-by":"crossref","unstructured":"Altebainawi AF, Alfaraj LA, Alharbi AA, Alkhuraisi FF, Alshammari TM. Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database. Ther Adv Drug Saf. 2023;14:1\u201310.","DOI":"10.1177\/20420986231154075"},{"key":"2025122201304625408_j_med-2025-1297_ref_003","doi-asserted-by":"crossref","unstructured":"Mori H, Suzuki H. Role of acid suppression in acid-related diseases:proton pump inhibitor and potassium-competitive acid blocker. J Neurogastroenterol Motil. 2019;25(1):6\u201314.","DOI":"10.5056\/jnm18139"},{"key":"2025122201304625408_j_med-2025-1297_ref_004","doi-asserted-by":"crossref","unstructured":"Zeng YF, Dai Y, Zhou ZY, Yu XB, Shi DW. Hepatotoxicity-related adverse effects of proton pump inhibitors: a cross-sectional study of signal mining and analysis of the FDA adverse event report system database. Front Med. 2021;8:648164.","DOI":"10.3389\/fmed.2021.648164"},{"key":"2025122201304625408_j_med-2025-1297_ref_005","doi-asserted-by":"crossref","unstructured":"Yibirin M, De Oliveira D, Valera R, Plitt AE, Lutgen S. Adverse effects associated with proton pump inhibitor use. Cureus. 2021;13(1):e12759.","DOI":"10.7759\/cureus.12759"},{"key":"2025122201304625408_j_med-2025-1297_ref_006","doi-asserted-by":"crossref","unstructured":"Kaczmarczyk O, Przybylska-Felu\u015b M, Pi\u0105tek-Guziewicz A, Wcislo K, Krosniak M, Kryczyk-Koziol J, et al. Effect of long-term proton pump inhibitor therapy on complete blood count parameters and selected trace elements: a pilot study. Pol Arch Intern Med. 2020;130(3):179\u201386.","DOI":"10.20452\/pamw.15101"},{"key":"2025122201304625408_j_med-2025-1297_ref_007","doi-asserted-by":"crossref","unstructured":"Danese E, Montagnana M, Favaloro EJ, Lippi G. Drug-induced thrombocytopenia: mechanisms and laboratory diagnostics. Semin Thromb Hemost. 2020;46(3):264\u201374.","DOI":"10.1055\/s-0039-1697930"},{"key":"2025122201304625408_j_med-2025-1297_ref_008","doi-asserted-by":"crossref","unstructured":"Bakchoul T, Marini I. Drug-associated thrombocytopenia. Hematology. 2018;2018:576\u201383.","DOI":"10.1182\/asheducation-2018.1.576"},{"key":"2025122201304625408_j_med-2025-1297_ref_009","doi-asserted-by":"crossref","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharacol Ther. 1981;30(2):239\u201345.","DOI":"10.1038\/clpt.1981.154"},{"key":"2025122201304625408_j_med-2025-1297_ref_010","doi-asserted-by":"crossref","unstructured":"Li C, Xu BF, Zhang M, Song YM, Liu R. Severe thrombocytopenia with acute cerebral infarction: a case report and literature review. Niger J Clin Pract. 2023;26(7):1040\u20134.","DOI":"10.4103\/njcp.njcp_844_22"},{"key":"2025122201304625408_j_med-2025-1297_ref_011","doi-asserted-by":"crossref","unstructured":"Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z. JBI manual for evidence synthesis. North Adelaide Australia: JBI; 2024.","DOI":"10.46658\/JBIMES-24-01"},{"key":"2025122201304625408_j_med-2025-1297_ref_012","doi-asserted-by":"crossref","unstructured":"Mukherjee S, Jana T, Pan JJ. Adverse effects of proton pump inhibitors on platelet count: a case report and review of the literature. Case Rep Gastrointest Med. 2018;2018:4294805.","DOI":"10.1155\/2018\/4294805"},{"key":"2025122201304625408_j_med-2025-1297_ref_013","unstructured":"Liu MC, Han Y. Two cases of thrombocytopenic purpura induced by omeprazole. People\u2019s Military Surg. 2015;58(2):190."},{"key":"2025122201304625408_j_med-2025-1297_ref_014","doi-asserted-by":"crossref","unstructured":"Saad M, Mitwally H. Lansoprazole-induced thrombocytopenia in a critically ill patient: a case report. J Pharm Pract. 2020;33(5):700\u20134.","DOI":"10.1177\/0897190019838681"},{"key":"2025122201304625408_j_med-2025-1297_ref_015","doi-asserted-by":"crossref","unstructured":"Zlabek JA, Anderson CG. Lansoprazole-induced thrombocytopenia. Ann Pharmacother. 2002;36(5):809\u201311.","DOI":"10.1345\/aph.1A303"},{"key":"2025122201304625408_j_med-2025-1297_ref_016","unstructured":"Deng YH, Xu J, Wang Y. One case of serious thrombocytopenia induced by lansoprazole and meropenem for injection. Chin J New Drugs Clin Rem. 2017;36(1):56\u20138."},{"key":"2025122201304625408_j_med-2025-1297_ref_017","unstructured":"Zheng XM, Wen Y. Thrombocytopenia induced by lansoprazole for injection. Chin J Drug Appl Monit. 2013;10(6):363\u20134."},{"key":"2025122201304625408_j_med-2025-1297_ref_018","doi-asserted-by":"crossref","unstructured":"Yu Z, Hu J, Hu YJ. Neutropenia and thrombocytopenia induced by proton pump inhibitors: a case report. Drug Saf \u2013 Case Rep. 2018;5(1):28.","DOI":"10.1007\/s40800-018-0093-0"},{"key":"2025122201304625408_j_med-2025-1297_ref_019","doi-asserted-by":"crossref","unstructured":"Phan AT, Tseng AW, Choudhery MW, Makar JB, Nguyen C, Farmand F. Pantoprazole-associated thrombocytopenia: a literature review and case report. Cureus. 2022;14(2):e22326.","DOI":"10.7759\/cureus.22326"},{"key":"2025122201304625408_j_med-2025-1297_ref_020","doi-asserted-by":"crossref","unstructured":"Korkmaz U, Alcelik A, Eroglu M, Korkmaz AN, Aktas G. Pantoprazole-induced thrombocytopenia in a patient with upper gastrointestinal bleeding. Blood Coagul Fibrinolysis. 2013;24(3):352\u20133.","DOI":"10.1097\/MBC.0b013e3283574f2f"},{"key":"2025122201304625408_j_med-2025-1297_ref_021","doi-asserted-by":"crossref","unstructured":"Widyati, Latifah N, Ramadhani M. Pantoprazole-induced thrombocytopenia: unresponsive to corticosteroid and thrombocyte concentrate transfusion. J Pharm Pract. 2023;36(3):711\u20135.","DOI":"10.1177\/08971900211064715"},{"key":"2025122201304625408_j_med-2025-1297_ref_022","doi-asserted-by":"crossref","unstructured":"Miller JL, Gormley AK, Johnson PN. Pantoprazole-induced thrombocytopenia. Indian J Pediatr. 2009;76(12):1278\u201399.","DOI":"10.1007\/s12098-009-0224-9"},{"key":"2025122201304625408_j_med-2025-1297_ref_023","doi-asserted-by":"crossref","unstructured":"Watson TD, Stark JE, Vesta KS. Pantoprazole-induced thrombocytopenia. Ann Pharmacother. 2006;40(4):758\u201361.","DOI":"10.1345\/aph.1G384"},{"key":"2025122201304625408_j_med-2025-1297_ref_024","doi-asserted-by":"crossref","unstructured":"Kallam A, Singla A, Silberstein P. Proton pump induced thrombocytopenia: a case report and review of literature. Platelets. 2015;26(6):598\u2013601.","DOI":"10.3109\/09537104.2014.953045"},{"key":"2025122201304625408_j_med-2025-1297_ref_025","doi-asserted-by":"crossref","unstructured":"Tas A. Thrombocytopenia as a side effect of pantoprazole. Turk J Gastroenterol. 2013;24(3):295\u20136.","DOI":"10.4318\/tjg.2013.0526"},{"key":"2025122201304625408_j_med-2025-1297_ref_026","doi-asserted-by":"crossref","unstructured":"Sahad, Jeevan RN, David S. A case report on pantoprazole-induced thrombocytopenia. Int J Pharm Sci Rev Res. 2024;84(1):111\u20132.","DOI":"10.47583\/ijpsrr.2024.v84i01.017"},{"key":"2025122201304625408_j_med-2025-1297_ref_027","unstructured":"Xie MZ, Xu XX, Zeng MF. One case of leukopenia and thrombocytopenia induced by injection of pantoprazole sodium. China Pharmacist. 2017;20(9):1611\u201353."},{"key":"2025122201304625408_j_med-2025-1297_ref_028","doi-asserted-by":"crossref","unstructured":"Binneto\u011flu E, Akbal E, \u015een H, G\u00fcnes F, Erbag G, Asik M, et al. Pantoprazole-induced thrombocytopenia in patients with upper gastrointestinal bleeding. Platelets. 2015;26(1):10\u20132.","DOI":"10.3109\/09537104.2014.880108"},{"key":"2025122201304625408_j_med-2025-1297_ref_029","doi-asserted-by":"crossref","unstructured":"Dotan E, Katz R, Bratcher J, Wasserman C, Liebman M, Panagopoulous G, et al. The prevalence of pantoprazole associated thrombocytopenia in a community hospital. Expert Opin Pharmacother. 2007;8(13):2025\u20138.","DOI":"10.1517\/14656566.8.13.2025"},{"key":"2025122201304625408_j_med-2025-1297_ref_030","doi-asserted-by":"crossref","unstructured":"De Silva E, Kim H. Drug-induced thrombocytopenia focus on platelet apoptosis. Chem Biol Interact. 2018;284:1\u201311.","DOI":"10.1016\/j.cbi.2018.01.015"}],"container-title":["Open Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2025-1297\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2025-1297\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T01:34:34Z","timestamp":1766367274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2025-1297\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10,31]]},"published-print":{"date-parts":[[2025,10,31]]}},"alternative-id":["10.1515\/med-2025-1297"],"URL":"https:\/\/doi.org\/10.1515\/med-2025-1297","relation":{},"ISSN":["2391-5463"],"issn-type":[{"type":"electronic","value":"2391-5463"}],"subject":[],"published":{"date-parts":[[2025,1,1]]},"article-number":"20251297"}}